Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety, pharmacokinetics and pharmacodynamics of AMG 557 in systemic lupus erythematosus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• AMG 557

Snippet

Sponsor: Amgen | Conditions: Systemic Lupus Erythematosus | Phase 1 | Status: COMPLETED